Petryk M, Grossbard M L
St. Luke's-Roosevelt Hospital Center, New York, NY 10019, USA.
Clin Lymphoma. 2000 Dec;1(3):186-94; discussion 195-6. doi: 10.3816/clm.2000.n.015.
The development of rituximab, an anti-CD20 monoclonal antibody, represents a revolutionary advance in the therapy of hematological malignancies. Rituximab was approved in 1997 by the Food and Drug Administration for the treatment of relapsed or refractory, CD20(+), B-cell, low-grade or follicular non-Hodgkin's lymphoma (NHL). Recent studies have documented activity of rituximab in other CD20-expressing hematological malignancies including mantle cell lymphoma, small lymphocytic lymphoma, aggressive NHL, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. When used in combination with cytotoxic chemotherapy, rituximab achieves response rates of 90%-95% in low-grade follicular and aggressive NHL patients. Currently, rituximab is undergoing intensive investigation in several large phase II and III trials, both as a single agent and in combination with chemotherapy. Clinical research will help define the ultimate role of this agent and its potential impact on survival of patients with B-cell neoplasms. This article describes current clinical trials with rituximab and discusses their significance.
抗CD20单克隆抗体利妥昔单抗的研发代表了血液系统恶性肿瘤治疗的一项革命性进展。1997年，利妥昔单抗被美国食品药品监督管理局批准用于治疗复发或难治性、CD20阳性、B细胞、低度或滤泡性非霍奇金淋巴瘤（NHL）。最近的研究已证明利妥昔单抗在其他表达CD20的血液系统恶性肿瘤中具有活性，包括套细胞淋巴瘤、小淋巴细胞淋巴瘤、侵袭性NHL、慢性淋巴细胞白血病和华氏巨球蛋白血症。当与细胞毒性化疗联合使用时，利妥昔单抗在低度滤泡性和侵袭性NHL患者中可达到90%-95%的缓解率。目前，利妥昔单抗正在多项大型II期和III期试验中接受深入研究，试验中它既可作为单一药物，也可与化疗联合使用。临床研究将有助于明确该药物的最终作用及其对B细胞肿瘤患者生存的潜在影响。本文介绍了目前使用利妥昔单抗的临床试验并讨论了其意义。
